These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14969457)

  • 41. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SSRIs and mammoplasia.
    Marcus P
    Am J Psychiatry; 2001 Jun; 158(6):967. PubMed ID: 11384918
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 45. Bayesian informative dropout model for longitudinal binary data with random effects using conditional and joint modeling approaches.
    Chan JS
    Biom J; 2016 May; 58(3):549-69. PubMed ID: 26467236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluvoxamine: safety profile in extensive post-marketing surveillance.
    Buchberger R; Wagner W
    Pharmacopsychiatry; 2002 May; 35(3):101-8. PubMed ID: 12107854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GEE for multinomial responses using a local odds ratios parameterization.
    Touloumis A; Agresti A; Kateri M
    Biometrics; 2013 Sep; 69(3):633-40. PubMed ID: 23724948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antisocial ideation and activities precipitated by the administration of SSRIs.
    Glancy GD
    Can J Psychiatry; 1993 Dec; 38(10):695. PubMed ID: 8313312
    [No Abstract]   [Full Text] [Related]  

  • 49. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy.
    Schmidt U; Cooper PJ; Essers H; Freeman CP; Holland RL; Palmer RL; Shur E; Russell GF; Bowler C; Coker S; Geddes JR; Mackenzie F; Munro J; Newton R; Tiller J; Tattersall ML; Vize C; Webster J
    J Clin Psychopharmacol; 2004 Oct; 24(5):549-52. PubMed ID: 15349014
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.
    Anderson IM; Tomenson BM
    BMJ; 1995 Jun; 310(6992):1433-8. PubMed ID: 7613276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms.
    Silver H; Aharon N; Kaplan A
    Schizophr Bull; 2003; 29(3):541-6. PubMed ID: 14609247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
    Moore ML; Eichner SF; Jones JR
    Ann Pharmacother; 2004 Sep; 38(9):1515-9. PubMed ID: 15292500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Marginal analysis of longitudinal ordinal data with misclassification in both response and covariates.
    Chen Z; Yi GY; Wu C
    Biom J; 2014 Jan; 56(1):69-85. PubMed ID: 24123126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.
    Ständer S; Böckenholt B; Schürmeyer-Horst F; Weishaupt C; Heuft G; Luger TA; Schneider G
    Acta Derm Venereol; 2009; 89(1):45-51. PubMed ID: 19197541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An application of maximum likelihood and generalized estimating equations to the analysis of ordinal data from a longitudinal study with cases missing at random.
    Kenward MG; Lesaffre E; Molenberghs G
    Biometrics; 1994 Dec; 50(4):945-53. PubMed ID: 7787007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Handling drop-out in longitudinal studies.
    Hogan JW; Roy J; Korkontzelou C
    Stat Med; 2004 May; 23(9):1455-97. PubMed ID: 15116353
    [TBL] [Abstract][Full Text] [Related]  

  • 58. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
    Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002791. PubMed ID: 17636706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluvoxamine and sleep disturbances in posttraumatic stress disorder.
    Neylan TC; Metzler TJ; Schoenfeld FB; Weiss DS; Lenoci M; Best SR; Lipsey TL; Marmar CR
    J Trauma Stress; 2001 Jul; 14(3):461-7. PubMed ID: 11534878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence.
    Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
    Cochrane Database Syst Rev; 2000; (4):CD002791. PubMed ID: 11034764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.